Literature DB >> 21079182

Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study.

S L Kirvell1, M S Elliott, R N Kalaria, T Hortobágyi, C G Ballard, P T Francis.   

Abstract

OBJECTIVES: Vascular dementia (VaD) accounts for approximately 15%-20% of all dementias, but the relationship of progressive cognitive impairment to neurochemical changes is poorly understood. We have therefore investigated glutamatergic synaptic markers in VaD.
METHODS: We used homogenates prepared from gray matter from 2 neocortical regions (Brodmann area [BA] 9 and BA 20) and Western blotting to determine the concentrations of key components of the glutamatergic neurotransmitter system, vesicular glutamate transporter 1 (VGLUT1) and excitatory amino acid transporter EAAT2 (GLT-1), and the ubiquitous synaptic protein, synaptophysin, in 73 individuals-48 patients with cerebrovascular disease with and without dementia, 10 patients with AD, and 15 controls-in a case-control design.
RESULTS: VGLUT1 concentrations in BA 20 and BA 9 were correlated with CAMCOG total (Rs 0.525, p = 0.018, n = 20; Rs 0.560, p = 0.002, n = 27) and CAMCOG memory scores (Rs 0.616, p = 0.004, n = 20; Rs 0.675, p = 0.000, n = 27). VGLUT1 concentration in BA 9 differed between the different dementia groups and the stroke no dementia group (1-way analysis of variance F = 6.69, p = 0.001 and Bonferroni p < 0.01 in each case), with subjects with stroke who did not develop dementia exhibiting the highest mean value for VGLUT1.
CONCLUSIONS: These data suggest that loss of glutamatergic synapses is a feature of VaD and Alzheimer disease but the preservation of synapses, in particular glutamatergic synapses, in the frontal cortex against the temporal cortex plays a role in sustaining cognition and protecting against dementia following a stroke.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079182      PMCID: PMC2995382          DOI: 10.1212/WNL.0b013e3181fd6328

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

Review 2.  Memantine for dementia.

Authors:  Sastre A Areosa; F Sherriff; R McShane
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

3.  Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease.

Authors:  Sara L Kirvell; Margaret Esiri; Paul T Francis
Journal:  J Neurochem       Date:  2006-08       Impact factor: 5.372

Review 4.  Excitotoxicity in neurological disorders--the glutamate paradox.

Authors:  T P Obrenovitch; J Urenjak; E Zilkha; T M Jay
Journal:  Int J Dev Neurosci       Date:  2000 Apr-Jun       Impact factor: 2.457

5.  Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology.

Authors:  Johannes Attems; Magdalena Quass; Kurt A Jellinger; Felix Lintner
Journal:  J Neurol Sci       Date:  2007-02-15       Impact factor: 3.181

Review 6.  Towards defining the neuropathological substrates of vascular dementia.

Authors:  Raj N Kalaria; Rose Anne Kenny; Clive G Ballard; Robert Perry; Paul Ince; Tuomo Polvikoski
Journal:  J Neurol Sci       Date:  2004-11-15       Impact factor: 3.181

7.  Clinicopathological validation study of four sets of clinical criteria for vascular dementia.

Authors:  Gabriel Gold; Constantin Bouras; Alessandra Canuto; Maria Fernanda Bergallo; François R Herrmann; Patrick R Hof; Pierre-André Mayor; Jean-Pierre Michel; Panteleimon Giannakopoulos
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

Review 8.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards.

Authors:  Vladimir Hachinski; Costantino Iadecola; Ron C Petersen; Monique M Breteler; David L Nyenhuis; Sandra E Black; William J Powers; Charles DeCarli; Jose G Merino; Raj N Kalaria; Harry V Vinters; David M Holtzman; Gary A Rosenberg; Anders Wallin; Martin Dichgans; John R Marler; Gabrielle G Leblanc
Journal:  Stroke       Date:  2006-08-17       Impact factor: 7.914

10.  Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors.

Authors:  Michael J Firbank; Emma J Burton; Robert Barber; Sally Stephens; Rose Anne Kenny; Clive Ballard; Raj N Kalaria; John T O'Brien
Journal:  Neurobiol Aging       Date:  2006-08-24       Impact factor: 4.673

View more
  9 in total

1.  Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.

Authors:  Sophie Sokolow; Sanh H Luu; Karabi Nandy; Carol A Miller; Harry V Vinters; Wayne W Poon; Karen H Gylys
Journal:  Neurobiol Dis       Date:  2011-09-03       Impact factor: 5.996

Review 2.  Breathing Exercises for Improving Cognitive Function in Patients with Stroke.

Authors:  Eui-Soo Kang; Jang Soo Yook; Min-Seong Ha
Journal:  J Clin Med       Date:  2022-05-20       Impact factor: 4.964

3.  Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies.

Authors:  Nicole Chow; Dag Aarsland; Hedieh Honarpisheh; Mona K Beyer; Johanne H Somme; David Elashoff; Arvid Rongve; Ole B Tysnes; Paul M Thompson; Liana G Apostolova
Journal:  Dement Geriatr Cogn Disord       Date:  2012-08-20       Impact factor: 2.959

Review 4.  Drug therapy of post-stroke aphasia: a review of current evidence.

Authors:  Marcelo L Berthier; Friedemann Pulvermüller; Guadalupe Dávila; Natalia García Casares; Antonio Gutiérrez
Journal:  Neuropsychol Rev       Date:  2011-08-16       Impact factor: 7.444

Review 5.  Update on the Neurobiology of Vascular Cognitive Impairment: From Lab to Clinic.

Authors:  Luisa Vinciguerra; Giuseppe Lanza; Valentina Puglisi; Francesco Fisicaro; Manuela Pennisi; Rita Bella; Mariagiovanna Cantone
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

6.  EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review.

Authors:  Oliver W G Wood; Jason H Y Yeung; Richard L M Faull; Andrea Kwakowsky
Journal:  Front Neurosci       Date:  2022-08-10       Impact factor: 5.152

7.  Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia.

Authors:  Arnab Datta; Jingru Qian; Ruifen Chong; Raj N Kalaria; Paul Francis; Mitchell K P Lai; Christopher P Chen; Siu Kwan Sze
Journal:  J Proteomics       Date:  2014-01-19       Impact factor: 4.044

Review 8.  Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease.

Authors:  Raj N Kalaria
Journal:  Acta Neuropathol       Date:  2016-04-09       Impact factor: 17.088

9.  Ischemia-Induced Cognitive Impairment Is Improved via Remyelination and Restoration of Synaptic Density in the Hippocampus after Treatment with COG-Up® in a Gerbil Model of Ischemic Stroke.

Authors:  Tae-Kyeong Lee; Junkee Hong; Ji-Won Lee; Sung-Su Kim; Hyejin Sim; Jae-Chul Lee; Dae Won Kim; Soon Sung Lim; Il Jun Kang; Moo-Ho Won
Journal:  Vet Sci       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.